Problematika CMV infektu u pacientů po alogenní transplantaci krvetvorných kmenových buněk

Eva Vejražková: Human Cytomegalovirus Infection in Patients after Allogeneic Hematopoietic Stem Cell Transplantation - Summary Introduction: Specific anti-cytomegalovirus (CMV) treatment reduces CMV-related morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT) but carries a risk of viral resistance. The viral resistance after HSCT treatment is still a relatively unexplored phenomenon. The aim of the study was to determine the incidence of CMV infection in patients within one year after HSCT in our centre. The goal was also to analyse CMV infection data, incidence of graft-versus-host disease and other clinical endpoints by comparing two patients' cohorts that were administered two different Thymoglobuline Genzyme (TG) doses as part of the HSCT conditioning regimen. Incidence of treatment failure cases and viral CMV drug resistance were also to be determined. Two methods of sequence analysis (Sanger and Next-Generation Sequencing, NGS) were compared in cases of proven viral resistance. Patients cohort and methods: The study included 101 adult patients after allogeneic HSCT for haematological diseases treated between July 2012 and December 2014 at the Hradec Kralove University Hospital, Czech Republic. CMV DNAemia was determined by quantitative real-time PCR, the...